Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus temozolomide versus temozolomide alone after radiotherapy in children and young adults with newly diagnosed high-grade glioma
NL-OMON59777Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in glioma comparing Abemaciclib plus temozolomide with Temozolomide monotherapy (2 arms). Primary endpoint: Event Free Survival as Determined by Blinded Independent Review Committee. Started May 2025; status: completed.
02
Drugs
abemaciclibtemozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on NL-OMON59777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59777.